Company intelligence / Profile preview

Rehaler

Ownership: Private
Development stage: Other

Overview

Rehaler's device-based therapy for migraine has entered clinical trials and received significant funding to expand its studies. The company aims to provide an individualized treatment plan using guided CO₂/oxygen modulation to stop migraine attacks. Recent investments have enabled the company to quadruple its number of ongoing clinical trials and move toward regulatory approval in key markets such as the US and EU.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

European Innovation Council Accelerator program (funding partner)

Beyond the preview

Go deeper on Rehaler.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rehaler.

Explore the full profile